A recent comparison between the cfDNA blood test (cell-free DNA) and our FOB Gold (Fecal Immunochemical Test – FIT) highlighted the superiority of FIT in detecting advanced precancerous lesions (APCL) while maintaining high specificity.
More specifically, the study published in Cancer Communications (May 2025) shows that:
- FOB Gold demonstrated more than twice the sensitivity of the cfDNA test in detecting APCL (31.5% vs. 13.2%).
- FIT showed higher specificity (93.3% vs. 89.6%), reducing the number of false positives.
- For the combined detection of CRC and APCL, FIT outperformed cfDNA (35.4% vs. 17.0%).
These findings reinforce the relevance of FIT as a first-line screening tool, already adopted in several national organized screening programs, such as in the Netherlands.
Conclusion:
While blood-based tests offer promising simplicity, FOB Gold remains the most effective non-invasive standard for high-quality early detection — particularly as part of an organized program.
